Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, Ziemssenstraße, Munich, Germany.
Divis ion of Internal Medicine and Hypertension, Department of Medical Sciences, University of Turin, Turin, Italy.
J Clin Endocrinol Metab. 2020 Mar 1;105(3):e484-93. doi: 10.1210/clinem/dgz051.
High dietary salt intake is known to aggravate arterial hypertension. This effect could be of particular relevance in the setting of primary aldosteronism (PA), which is associated with cardiovascular damage independent of blood pressure levels. The aim of this study was to determine the impact of therapy on salt intake in PA patients.
A total of 148 consecutive PA patients (66 with unilateral and 82 with bilateral PA) from the database of the German Conn's Registry were included. Salt intake was quantified by 24-hour urinary sodium excretion before and after initiation of PA treatment.
Observational longitudinal cohort study.
Tertiary care hospital.
At baseline, unilateral PA patients had a significantly higher urinary sodium excretion than patients with bilateral disease (205 vs 178 mmol/d, P = 0.047). Higher urinary sodium excretion correlated with an increased cardiovascular risk profile including proteinuria, impaired lipid, and glucose metabolism and was associated with higher daily doses of antihypertensive drugs to achieve blood pressure control. In unilateral disease, urinary sodium excretion dropped spontaneously to 176 mmol/d (P = 0.012) 1 year after unilateral adrenalectomy and remained low at 3 years of follow-up (174 mmol/d). In contrast, treatment with mineralocorticoid receptor antagonists (MRA) in bilateral PA patients was not associated with a significant change in urinary sodium excretion at follow-up (179 mmol/d vs 183 mmol/d).
PA patients consuming a high-salt diet, estimated based on urinary sodium excretion, respond to adrenalectomy with a significant reduction of salt intake, in contrast to MRA treatment.
已知高盐饮食会加重动脉高血压。这种影响在原发性醛固酮增多症(PA)中可能尤为重要,因为PA 与心血管损害有关,而与血压水平无关。本研究旨在确定治疗对 PA 患者盐摄入量的影响。
从德国 Conn 登记处的数据库中纳入了 148 例连续的 PA 患者(单侧 66 例,双侧 82 例)。在开始治疗 PA 之前和之后,通过 24 小时尿钠排泄来量化盐摄入量。
观察性纵向队列研究。
三级保健医院。
在基线时,单侧 PA 患者的尿钠排泄量明显高于双侧疾病患者(205 与 178mmol/d,P=0.047)。更高的尿钠排泄与心血管风险增加的特征相关,包括蛋白尿、脂质和葡萄糖代谢受损,并且与实现血压控制所需的更高剂量的降压药物相关。在单侧疾病中,单侧肾上腺切除术 1 年后尿钠排泄自发降至 176mmol/d(P=0.012),并在 3 年随访时保持较低水平(174mmol/d)。相比之下,双侧 PA 患者接受盐皮质激素受体拮抗剂(MRA)治疗与随访时尿钠排泄无显著变化相关(179mmol/d 与 183mmol/d)。
根据尿钠排泄估计,摄入高盐饮食的 PA 患者在接受肾上腺切除术治疗后,盐摄入量会显著减少,而 MRA 治疗则不然。